On January 8, 2026, Truist Financial analysts increased their price target for CorMedix Therapeutics to $16, representing an 84.95% potential upside from current levels. This adjustment follows a prior target of $20, reflecting updated modeling that incorporates recent product launches and anticipated milestones in the company’s pipeline. The revised target underscores Truist’s confidence in CorMedix’s leading anti-infective franchise and its capacity to capture additional market share in hospital settings over the next 12–18 months.

CorMedix reported preliminary, unaudited net revenues of $127 million for the fourth quarter and $400 million for the full year 2025. The company also expects adjusted EBITDA of $77–$81 million for Q4, driven by robust sales growth of its lead product and disciplined cost management. As of year-end, CorMedix held approximately $148 million in cash and short-term investments, positioning the balance sheet to support ongoing clinical trials and commercialization efforts without the need for immediate capital raises.

Investors reacted negatively to CorMedix’s guidance for fiscal 2026 revenues of up to $320 million, down from the preliminary 2025 net revenue of $400 million. This conservative projection reflects anticipated pricing pressures and the timing of new clinical data readouts. Following the announcement, trading volumes surged and the share count traded near multi-month highs, signaling heightened volatility. Management emphasized that the guidance incorporates expected investment in market expansion and manufacturing scale-up, which should lay the groundwork for sustained growth beyond 2026.